Harrison Stephen A, Ratziu Vlad, Anstee Quentin M, Noureddin Mazen, Sanyal Arun J, Schattenberg Jörn M, Bedossa Pierre, Bashir Mustafa R, Schneider David, Taub Rebecca, Bansal Meena, Kowdley Kris V, Younossi Zobair M, Loomba Rohit
Pinnacle Clinical Research Center, San Antonio, Texas, USA.
Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Aliment Pharmacol Ther. 2024 Jan;59(1):51-63. doi: 10.1111/apt.17734. Epub 2023 Oct 2.
Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and fibrosis. In a Phase 2 trial in adults with NASH (NCT02912260), resmetirom, an orally administered, liver-targeted thyroid hormone receptor-β selective agonist, significantly reduced hepatic fat (via imaging) and resolved NASH without worsening fibrosis (via liver biopsy) in a significant number of patients compared with placebo.
To present the design of the Phase 3 MAESTRO clinical programme evaluating resmetirom for treatment of NASH (MAESTRO-NAFLD-1 [NCT04197479], MAESTRO-NAFLD-OLE [NCT04951219], MAESTRO-NASH [NCT03900429], MAESTRO-NASH-OUTCOMES [NCT05500222]).
MAESTRO-NASH is a pivotal serial biopsy trial in up to 2000 adults with biopsy-confirmed at-risk NASH. Patients are randomised to a once-daily oral placebo, 80 mg resmetirom, or 100 mg resmetirom. Liver biopsies are conducted at screening, week 52 and month 54. MAESTRO-NAFLD-1 is a 52-week safety trial in ~1400 adults with NAFLD/presumed NASH (based on non-invasive testing); ~700 patients from MAESTRO-NAFLD-1 are enrolled in MAESTRO-NAFLD-OLE, a 52-week active treatment extension to further evaluate safety. MAESTRO-NASH-OUTCOMES is enrolling 700 adults with well-compensated NASH cirrhosis to evaluate the potential for resmetirom to slow progression to hepatic decompensation events. Non-invasive tests (biomarkers, imaging) are assessed longitudinally throughout, in addition to validated patient-reported outcomes.
The MAESTRO clinical programme was designed in conjunction with regulatory authorities to support approval of resmetirom for treatment of NASH. The surrogate endpoints, based on week 52 liver biopsy, serum biomarkers and imaging, are confirmed by long-term clinical liver-related outcomes in MAESTRO-NASH (month 54) and MAESTRO-NASH-OUTCOMES (time to event).
非酒精性脂肪性肝炎(NASH)是一种非酒精性脂肪性肝病(NAFLD)的进展形式,与脂肪变性、肝细胞损伤、炎症和纤维化相关。在一项针对成人NASH患者的2期试验(NCT02912260)中,与安慰剂相比,口服给药的肝脏靶向甲状腺激素受体-β选择性激动剂瑞美替昂可显著降低肝脏脂肪(通过成像),并使大量患者的NASH得到缓解且未使纤维化恶化(通过肝活检)。
介绍评估瑞美替昂治疗NASH的3期MAESTRO临床项目的设计(MAESTRO-NAFLD-1 [NCT04197479]、MAESTRO-NAFLD-OLE [NCT04951219]、MAESTRO-NASH [NCT03900429]、MAESTRO-NASH-OUTCOMES [NCT05500222])。
MAESTRO-NASH是一项关键的系列活检试验,纳入多达2000例经活检确诊为有风险的NASH成人患者。患者被随机分配至每日一次口服安慰剂、80毫克瑞美替昂或100毫克瑞美替昂。在筛选时、第52周和第54个月进行肝活检。MAESTRO-NAFLD-1是一项针对约1400例NAFLD/疑似NASH成人患者(基于非侵入性检测)的为期52周的安全性试验;MAESTRO-NAFLD-1中的约700例患者被纳入MAESTRO-NAFLD-OLE,这是一项为期52周的活性治疗延长期试验,以进一步评估安全性。MAESTRO-NASH-OUTCOMES正在招募700例代偿良好的NASH肝硬化成人患者,以评估瑞美替昂减缓进展至肝失代偿事件的可能性。除了经过验证的患者报告结局外,并在整个过程中纵向评估非侵入性检测(生物标志物、成像)。
MAESTRO临床项目是与监管机构联合设计的,以支持瑞美替昂治疗NASH的获批。基于第52周肝活检、血清生物标志物和成像的替代终点,在MAESTRO-NASH(第54个月)和MAESTRO-NASH-OUTCOMES(至事件发生时间)中通过长期临床肝脏相关结局得到证实。